PKO Investment Management Joint Stock Co Sells 4,500 Shares of IQVIA Holdings Inc. $IQV

PKO Investment Management Joint Stock Co cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 56.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,500 shares of the medical research company’s stock after selling 4,500 shares during the period. PKO Investment Management Joint Stock Co’s holdings in IQVIA were worth $665,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Artisan Partners Limited Partnership acquired a new position in IQVIA in the 2nd quarter worth about $515,772,000. Norges Bank bought a new stake in shares of IQVIA during the second quarter worth about $270,160,000. AQR Capital Management LLC increased its stake in shares of IQVIA by 130.2% in the second quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares during the period. Laurel Wealth Advisors LLC raised its holdings in IQVIA by 15,755.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock valued at $122,857,000 after buying an additional 774,681 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in IQVIA by 41.7% during the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. BMO Capital Markets assumed coverage on IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price for the company. Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Stifel Nicolaus raised their price objective on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $249.19.

IQVIA Stock Up 0.5%

Shares of NYSE:IQV opened at $241.95 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The business’s 50-day moving average is $225.53 and its 200-day moving average is $201.95. The company has a market capitalization of $41.20 billion, a price-to-earnings ratio of 33.19, a P/E/G ratio of 2.45 and a beta of 1.36.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The business had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.